Melanotan I vs II is fundamentally a comparison of receptor selectivity: two synthetic analogs of alpha-melanocyte-stimulating hormone (α-MSH) that both activate the melanocortin system, but with markedly different affinity profiles across the five melanocortin receptor subtypes. For laboratories studying pigmentation biology, the distinction is not cosmetic — it defines which downstream signaling pathways a research model will engage. Melanotan I (afamelanotide) behaves as a comparatively MC1-focused agonist, while Melanotan II is a non-selective, superpotent agonist that binds MC1R, MC3R, MC4R, and MC5R. This article compares the two peptides through the lens of melanocortin receptor selectivity and its relevance to preclinical pigmentation research.
Research Use Only. Melanotan I and Melanotan II are supplied strictly for laboratory, in-vitro, and preclinical research use. They are not for human or veterinary use, are not dietary supplements, and have not been evaluated by the FDA. Nothing here is intended to diagnose, treat, cure, or prevent any disease, and no human dosing or administration guidance is provided.
The melanocortin system at a glance
Melanocortin peptides derive from the pro-opiomelanocortin (POMC) precursor and signal through a family of five G-protein-coupled receptors (MC1R–MC5R), each coupled primarily to Gs and adenylyl cyclase. Receptor activation raises intracellular cyclic AMP (cAMP), which drives tissue-specific responses. In melanocytes, cAMP elevation activates protein kinase A and the transcription factor MITF, upregulating tyrosinase and shifting melanin synthesis toward eumelanin. The receptor subtypes distribute differently across tissues, which is why a peptide's selectivity determines the biology it probes. For a deeper treatment of the pathway, see our Melanocortin System: Receptor Mechanism Guide.
Where each receptor sits
- MC1R — melanocytes; the primary node for pigmentation (eumelanin/pheomelanin ratio) research.
- MC2R — adrenal cortex; responds to ACTH, not to α-MSH analogs.
- MC3R / MC4R — central nervous system; investigated in energy balance, feeding, and sexual-response research.
- MC5R — exocrine glands; studied in sebaceous and lacrimal secretion models.
Melanotan I: the MC1-focused profile
Melanotan I is the linear tridecapeptide [Nle4, D-Phe7]-α-MSH, differing from native α-MSH by two substitutions that resist enzymatic degradation and extend half-life. While it is an agonist at multiple melanocortin receptors, in pigmentation research it is generally treated as a comparatively MC1-directed tool: its structure closely mirrors native α-MSH, and research models emphasize its melanogenic activity at MC1R without the pronounced central and MC4R-driven effects associated with the cyclic analog. This relatively cleaner MC1 engagement makes Melanotan I a useful probe when a study aims to isolate melanocyte cAMP/MITF signaling. Full structural and mechanistic detail is in the Melanotan I Research Guide.
Melanotan II: the non-selective superagonist
Melanotan II is a cyclic heptapeptide, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. Cyclization confers conformational rigidity and metabolic stability, producing high potency and — critically — broad, non-selective agonism across MC1R, MC3R, MC4R, and MC5R. This wide binding footprint is why Melanotan II is studied not only in pigmentation models but also as the parent scaffold behind MC4R-focused research on sexual-response pathways; the FDA-approved compound bremelanotide (PT-141) is a metabolite-derived analog of this lineage. See the Melanotan II Research Guide and the focused comparison in PT-141 vs Melanotan II.
Melanotan I vs II: side-by-side
| Attribute | Melanotan I (afamelanotide) | Melanotan II |
|---|---|---|
| Structure | Linear tridecapeptide [Nle4, D-Phe7]-α-MSH | Cyclic heptapeptide (lactam-bridged) |
| Receptor profile | Comparatively MC1-focused agonism | Non-selective: MC1R, MC3R, MC4R, MC5R |
| Relative potency | Potent at MC1R | Superpotent, broad melanocortin activation |
| Primary research use | Pigmentation / MC1R melanogenesis models | Broad melanocortin & MC4R pathway studies |
| Off-target breadth | Narrower | Wider (central MC3R/MC4R engagement) |
| Molecular size | Larger (13 residues) | Smaller (cyclic 7-residue core) |
What the selectivity difference means for a research model
The core experimental trade-off is specificity versus breadth. A researcher isolating MC1R-driven melanogenesis — for example, measuring tyrosinase induction or eumelanin output in cultured melanocytes — may prefer Melanotan I precisely because it engages the melanocyte pathway with fewer confounding central-receptor effects. A researcher characterizing pan-melanocortin signaling, or using pigmentation as a readout while also probing MC3R/MC4R-linked pathways, may select Melanotan II for its broad agonism. Neither is "better"; each maps onto a different research question. Our dedicated resource on Melanocortin Receptor Selectivity in Research expands on how binding-affinity ratios (Ki values across subtypes) are used to interpret these tools.
Signaling pathways engaged in pigmentation research
In both cases, MC1R activation in melanocyte models proceeds through a well-characterized cascade that researchers monitor as readouts:
- Receptor–ligand binding at MC1R on the melanocyte surface.
- Gs-coupled adenylyl cyclase activation, elevating cAMP.
- PKA activation and CREB phosphorylation, inducing MITF expression.
- Upregulation of tyrosinase, TRP-1, and TRP-2, the rate-limiting melanogenic enzymes.
- Shift toward eumelanin synthesis within melanosomes.
Because Melanotan II additionally engages MC3R/MC4R in central tissue models, studies using it must account for pathway activity beyond the melanocyte — a consideration absent when a more MC1-focused ligand is used.
Laboratory handling of research preparations
Both peptides are supplied as lyophilized powder and share standard peptide handling for research preparations:
- Storage: keep lyophilized material at −20 °C, protected from light and moisture; long-term storage is more stable frozen than refrigerated.
- Reconstitution: bacteriostatic or sterile water is typical for preparing stock solutions for in-vitro work; add diluent gently down the vial wall rather than directly onto the pellet.
- Post-reconstitution: store the solution refrigerated (2–8 °C) and minimize freeze–thaw cycles to preserve peptide integrity.
- Documentation: confirm identity and ≥99% purity against the third-party COA before experimental use.
NeuroLabs supplies both peptides as ≥99% purity, third-party COA-tested research material with same-day USA shipping. Explore Melanotan I 10mg and Melanotan II 10mg, and see the broader category pillar, Melanocortin & Reproductive Peptides, for related research tools.
Summary
Melanotan I and Melanotan II both activate the melanocortin system and drive melanogenesis through MC1R, but they diverge sharply in receptor selectivity: Melanotan I offers a comparatively MC1-focused profile suited to isolating melanocyte signaling, while Melanotan II is a non-selective superagonist that engages MC1R, MC3R, MC4R, and MC5R, making it a broader — and more central-active — research scaffold. Selecting between them is a matter of matching receptor breadth to the experimental question.